Yila
Förderrichtlinien 2026 · 53 bewilligte Originalanträge im X-Ray

Forschungsantrag erstellen

Analysieren Sie den Argumentationsaufbau bewilligter Anträge vor dem Schreiben. Prüfen Sie Themenüberschneidungen gegen 434.916 Förderprojekte und entwerfen Sie belastbare Arbeitsprogramme.

434.9k funded-award collision check · 100% verified DOIs · Zero fabricated prelim data · Zero verbatim copying

Try a concrete proposal scenario:
Scarce Authorized Collection · 67 Real Winning Proposals Dissected

2022–2024 Winning NSFC Proposal X-Ray Studio

Full winning NSFC proposals are exceptionally scarce. Yila curates 53 authorized 2022–2024 NSFC funded proposals (including 46 in Medicine H, spanning 31 General, 16 Young Scientist, and 6 Regional/International awards) plus 12 winning NSSFC anonymous sheets—deeply desensitized with section-by-section panel commentary.

Integrity & Privacy Notice: All PI names, departments, room numbers, and CVs have been scrubbed. Strictly read-only structural X-Ray—raw PDF downloads are never offered.
国自然 NSFC · 2024面上项目H0709 · 内分泌系统/代谢和营养支持

巡逻单核细胞介导训练免疫促进减重代谢术后复胖的机制研究

4-Move Scientific Hypothesis Chain

01临床疾病/功能表型痛点与前期预实验靶点锁定
02核心分子轴(巡逻单核细胞介导训练免疫促进减重代谢…)精细上下游互作解析
03基因条件性敲除/位点突变正反双向因果挽救验证(Rescue)
04体内动物模型与临床队列样本转化有效性闭环核验
Panel Reviewer X-Ray Verdict

面上项目 (50万+) 深度标杆:不仅完成细胞与动物表型确认,更深入到特定结构域/修饰位点突变回补(Rescue),因果链条密不透风。

2026 Reform Adaptation Note

原件共 21 页。按 2026 国自然「瘦身提质」新规迁移时,可将研究内容、目标、关键科学问题与研究方案统一收束进第二大板块【研究内容】,用 1 张主干技术路线图串联三层验证,全篇精炼控制在 25–30 页内。

Desensitized Chapter Excerpts & Reviewer X-Ray

板块一:立项依据核心破题脉络
析,需结合科学研究发展趋势来论述科学意义;或结合国民经济和社 会发展中迫切需要解决的关键科技问题来论述其应用前景。附主要参 考文献目录) ; 1.1 复胖是减重代谢外科领域目前亟待解决的难题 肥胖及能量代谢调节异常相关疾病是严重威胁人类健康的全球卫生问题,饮 食、运动及药物治疗效果往往不甚满意,减重代谢手术作为治疗肥胖及其相关并 发症的新技术应运而生。自 2000年起,我国减重代谢外科开始起步并迅猛发展, 现已在全国多个中心开展。目前主流术式包括 Roux-en-Y胃旁路术及袖状胃切除 术,其中,袖状胃切除术(Sleeve gastrectomy, SG)占比达到了 83%[1]。申请人团 队依托于国家临床重点专科([依托单位/科研平台]湘雅三医院普通外科) ,是我国最早开展 减重代谢手术的团队之一,长期致力于减重代谢手术的手术评价及远期随访研究, 证实减重代谢手术对患者糖尿病、心血管疾病均有显著改善,是肥胖及其相关并 发症治疗的最有效手段[2-5]。最新的循证医学证据还表明减重代谢手术可显著降低 肿瘤的发生率,使死亡风险降低 49.2%,中位预期寿命比常规治疗增长 6.1年[6,7]。 然而,在适应症不断拓宽、手术量日益增长的背景下,减重代谢手术正面临一个 难题:复胖。尽管目前尚无统一标准,但据文献报道其发生率可达 20%以上,在 SG中更是高达 27.8%,已经成为 SG术后备受关注的问题[8-10]。术后复胖患者更 容易发生代谢相关疾病的复发及进展,只需反弹较轻微的体重,就会逆转减肥带 来的血糖血脂改善等代谢益处[11,12]。Look AHEAD(糖尿病健康行动)试验数据表明, 复胖与患者心血管风险增加显著相关[13]。此外,10-20%的术后复胖患者一般治疗 无效,需要进行修正手术[10]。复胖的高发生率及其所致代谢风险升高给社会医疗 体系带来了沉重的负担。 目前,针对术后复胖的研究大多聚焦于预测环节,具体涉及解剖学、生活方 式、激素水平和精神心理状态等多个方面。然而,针对以上因素制定的防治手段 (包括术式、饮食、运动、药物和心理干预)尚未获得满意的成效。同时, 探索 术后复胖病理生理机制的研究匮乏,临床亦缺乏有效的防治方案和监测手段。
REVIEWER X-RAY面上项目 (50万+) 深度标杆:不仅完成细胞与动物表型确认,更深入到特定结构域/修饰位点突变回补(Rescue),因果链条密不透风。
板块二:研究内容与关键科学问题凝练
分为重点阐述内容); 2.1 研究内容 2.1.1揭示术后复胖中是否存在巡逻单核细胞的训练免疫并促进脂质蓄积 首先,收集复胖及减重成功患者外周血进行单细胞测序,寻找出具有差异性 的细胞亚群(巡逻单核细胞);然后构建肥胖-SG-复胖大鼠模型,在大鼠血液中 检测其比例,并观察复胖大鼠 V AT中 MDMs的比例、体脂分布、脂肪组织炎症、 脂肪细胞大小、脂解功能及代谢能力;最后,从大鼠骨髓中提取巡逻单核细胞进 行体外极化诱导,观察其极化基因表达和脂质蓄积功能的改变。 2.1.2明确巡逻单核细胞训练免疫是否可诱发术后复胖 首先,术后复胖大鼠和减重成功大鼠互为受供体进行骨髓移植;然后观察外 周血中巡逻单核细胞比例、V AT中 MDMs比例、体重、体脂分布、脂肪组织炎症、 脂肪细胞大小、脂解功能及代谢能力;最后提取移植后大鼠的外周血巡逻单核细 胞常规培养后进行体外极化诱导,观察其极化基因表达和脂质蓄积功能的改变。 2.1.3阐明复胖中巡逻单核细胞训练免疫的通路及机制 首先,筛查复胖大鼠巡逻单核细胞各代谢途径变化;然后观察有氧糖酵解改 变情况和 PERK信号通路的表达情况;最后,明确特异性抑制剂和 shRNA转染抑 制/敲低 PERK及抑制有氧糖酵解可否在细胞和动物层面阻断训练免疫。 2.2 研究目标 1)揭示术后复胖中存在巡逻单核细胞训练免疫诱导脂质蓄积的重要现象; 2)明确巡逻单核细胞训练免疫诱发术后复胖发生的关键作用; 3)阐明 PERK信号通路调控巡逻单核细胞有氧糖酵解介导训练免疫并诱发术 后复胖的机制。 2.3 拟解决的关键科学问题 本课题的关键科学问题是肥胖调控 PERK 信号通路诱导巡逻单核细胞有氧糖 酵解激活,介导训练免疫促进脂肪组织炎症和脂质蓄积,诱发减重代谢术后复胖。
REVIEWER X-RAY原件共 21 页。按 2026 国自然「瘦身提质」新规迁移时,可将研究内容、目标、关键科学问题与研究方案统一收束进第二大板块【研究内容】,用 1 张主干技术路线图串联三层验证,全篇精炼控制在 25–30 页内。
研究方案可行性与特色创新提炼
实验手段、关键技术等说明) ; 3.1 技术路线 总体技术路线 图 3.2 研究方案 3.2.1明确减重代谢手术后复胖中是否存在巡逻单核细胞训练免疫并促进脂质蓄积 (1) 复胖及减重成功患者单细胞测序筛选差异性细胞亚群及流式细胞术验证 收集复胖及减重成功患者外周血 PBMC行单细胞测序,分为复胖组及减重成 功组进行分析,寻找 2组间差异性细胞亚群并通过流式细胞学验证细胞比例。 关键技术: a)患者筛选和标本收集:以体重下降至最低点后,体重增加> 术前最大体重 的 35%为复胖标准,以术后 2年多余体重减轻百分比( (初始体重 – 术后体重)÷ (初始体重 – 理想体重) × 100%) )≥ 50%为减重成功标准。筛选 SG术后 2年发 生复胖及减重成功患者各 6位(年龄、性别及 BMI相匹配) ,于肘正中静脉抽取 10ml外周血暂存于 EDTA 抗凝管。 b) PBMC分离:将收集的新鲜抗凝血转入 20mL 离心管中,室温离心 10 min; 弃掉上层血浆,加入 1×PBS(pH 7.4),吹吸混匀;按照 Ficoll : 血细胞悬液 = 4 : 5 的比例将血液铺入,避免两层混合; 800 g,室温离心 25 min,离心后可见离心 管中呈现 4 层,由上至下依次为稀释液层、环状乳白色 PBMC 层、透明分离液层、 红细胞层。弃掉第一层稀释液层后沿管周缓慢收集白膜层至新 20mL 离心管中。 向收集管中缓慢加入 1×PBS至 18mL, 500 g,室温离心 10 min,离心后弃上层 液体,可见微黄色及红色沉淀;加入 2ml红细胞裂解液进行暗反应 3分钟后,500 g,室温离心 5min,得到沉淀后加入 PBS缓冲液,吹打混匀后再次以同样参数离 心 5分钟,加入 PBS缓冲液,取 10μL PBMC 悬液与等体积 Trypan Blue 染液混匀, 进行细胞计数,确定细胞活性达到 90%以上且无红细胞干扰,获得合格的细胞核 悬液备用。
REVIEWER X-RAY可行性切忌空喊“设备齐全”,务必点明核心基因工程动物品系、临床样本队列或高难度预实验技术节点已实质跑通。

Protected scholarly archive · Dynamic account watermark active; raw PDF downloads and bulk exports are disabled.

2026 Official Guidelines · Study Section Lens

2026 Reform Rubric & Empirical Budget Calculator

Compare C-grade rejected pitfalls against A-grade winning moves across the 2026 NSFC <=30-page 3-section reform and 2026 NSSFC <=7,000-character anonymous sheet rules.

Part 01Abstract <=400 chars · Concise Rationale

400-Char Abstract & Scientific Rationale

Open directly on the unresolved clinical or engineering bottleneck, pair narrowed literature gaps with preliminary evidence, and lock in one falsifiable central hypothesis.

C-Grade Rejected Pitfall (Avoid)

Two pages of textbook overview ("In recent years…") and uncritical citation dumping before stating the research question on page 6.

A-Grade Winning Move (53-Exemplar Standard)

Sentence 1 names the concrete failure mode; each literature block ends with a sharp mechanistic gap, bridged immediately by 2–3 preliminary findings into the central hypothesis.

Part 02Merged Core · Zero Domino Aims

Research Content, Bottlenecks & Parallel Plan

Consolidates content, key scientific questions, technical approach, feasibility, and novelty into a cohesive 3-aim architecture with explicit contingencies.

C-Grade Rejected Pitfall (Avoid)

Listing assay names as "scientific questions", or making Aim 2/3 depend entirely on an unvalidated molecule screened in Aim 1.

A-Grade Winning Move (53-Exemplar Standard)

Formulate 1–2 mechanistic bottlenecks; anchor target identity in prelim data so Aims 1–3 validate phenotype, mechanism, and rescue in parallel with Plan B fallbacks.

Part 03Target <=30 pages · 4–6 High-Density Figures

Track Record, Conditions & <=30-Page Discipline

Demonstrates execution credibility: prior publications tied to this hypothesis, established animal/clinical cohorts, and core facility access.

C-Grade Rejected Pitfall (Avoid)

Padding to 55+ pages, listing unrelated co-authored papers, or pasting preliminary plots without scale bars, n-values, or statistical tests.

A-Grade Winning Move (53-Exemplar Standard)

25–30 crisp pages featuring 1 overall hypothesis diagram, 1 technical roadmap Gantt chart, and 3–4 rigorously annotated preliminary figure panels.

The 5-Move 400-Char Winning Abstract Formula (Distilled from 53 Funded NSFC Proposals)
1. Unresolved Bottleneck (~15%)Name the clinical resistance or engineering failure mode in sentence one.
2. Preliminary Hook (~22%)Anchor in observed cohort/experimental evidence linking factor X to phenotype D.
3. Central Hypothesis (~20%)State falsifiably how A regulates B via pathway C to drive D.
4. Three Parallel Aims (~28%)Phenotypic validation, molecular mechanism dissection, and targeted intervention.
5. Scientific & Translational Payoff (~15%)Define the mechanistic advance and biomarker/therapeutic target within <=400 chars.
Empirical NSFC Direct-Budget Calculator (53 Winning Proposal Mean)

Enter your target direct funding (in ¥10k CNY / Wanyuan) to compute empirical line-item benchmarks derived from real funded NSFC budget tables.

× ¥10k CNY
Research Materials & Consumables (51.5%)15.5 × ¥10k CNY
Sequencing, Assay & Testing Services (28.3%)8.5 × ¥10k CNY
Graduate & Postdoc Stipends / Labor (16.4%)4.9 × ¥10k CNY
Minor Equipment, Conferences & Other (3.8%)1.1 × ¥10k CNY
FAQ

Grant Proposal Writer & Winning Exemplar Archive

How does Yila adapt to the 2026 NSFC and NSSFC proposal reforms?

Yila enforces the 2026 NSFC three-section <=30-page consolidation (merging rationale, research content/plan, and track record while eliminating redundant repetition) and the 2026 NSSFC anonymous sheet rules (<=300-char Topic Justification, <=7,000-char ceiling, and strict zero-identity double-blind checks).

Where do the 67 winning proposal exemplars come from, and can raw PDFs be downloaded?

The collection comprises 53 authorized 2022–2024 funded NSFC proposals (31 General, 16 Young Scientist, 6 Regional/International—including 46 in Medicine H), 12 winning NSSFC anonymous sheets, and 2 clinical specials. Every exemplar undergoes deep secondary PII scrubbing and dynamic account watermarking; raw PDF downloads are strictly disabled.

Does binding an exemplar skeleton risk plagiarism or text overlap?

Never. When an exemplar skeleton is bound or queried by the Agent, the backend transmits only structural chapter progression, aim-decoupling logic, reviewer X-Ray notes, and budget ratios—zero raw proposal prose enters generation.

Are citations verified, and how is preliminary data handled?

Every reference is verified against OpenAlex, PubMed, Crossref, or Wanfang (when conversing in Chinese) with real DOIs. Yila never fabricates preliminary experimental numbers or figures; unmeasured evidence gaps are explicitly marked for the PI to supply.

Can I upload an unapproved proposal from last year along with reviewer critiques?

Yes. Use "Attach Prior Draft / Critiques" in the composer to upload both your previous draft and panel comments. Yila diagnoses structural flaws (such as dominoed aims or vague scientific bottlenecks) while preserving all genuine preliminary results.

Which plans unlock all 67 winning proposal X-Rays?

Visitors and Free/Monthly users can inspect featured sample exemplars and the full 2026 Rubric & Budget Calculator. Every Yearly plan (Starter, Pro, Flagship Yearly) and every Lifetime pack (Starter $249, Pro $499, Flagship $1,999 Lifetime) unlocks all 67 winning exemplars (up to 20 full inspections/day) plus all 434,916 grant records.